EDAP Berita Valas

EDAP TMS Says FDA Grants Breakthrough Designation To Focal One For Rectal Endometriosis

EDAP TMS SA (EDAP) announced Monday that its Focal One platform has been granted Breakthrough Device designation by the US Food and Drug Administration (FDA) for the treatment of deep infiltrating endometriosis (DIE).

RTTNews | 520 days ago

Terms | Privacy | Site Map | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.1585	GBPUSD	1.3299	AUDUSD	0.6493
USDJPY	147.811	USDCAD	1.37683	USDCHF	0.80816

Advertisement

EDAP Berita Valas

EDAP TMS Says FDA Grants Breakthrough Designation To Focal One For Rectal Endometriosis